Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1613-7671
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Ruxolitinib therapy for myelofibrosis in Austria ; volume:130 ; number:17-18 ; day:24 ; month:7 ; year:2018 ; pages:495-504 ; date:9.2018
Wiener klinische Wochenschrift ; 130, Heft 17-18 (24.7.2018), 495-504, 9.2018
- Creator
- Contributor
-
Burgstaller, Sonja
Buxhofer-Ausch, Veronika
Gastl, Günther
Geissler, Klaus
Keil, Felix
Krippl, Peter
Melchardt, Thomas
Petzer, Andreas
Rumpold, Holger
Sliwa, Thamer
Wöhrer, Stefan
Wölfler, Albert
Gisslinger, Heinz
SpringerLink (Online service)
- DOI
-
10.1007/s00508-018-1365-5
- URN
-
urn:nbn:de:101:1-2018102722512925516279
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
18.08.1970, 12:51 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Krauth, Maria
- Burgstaller, Sonja
- Buxhofer-Ausch, Veronika
- Gastl, Günther
- Geissler, Klaus
- Keil, Felix
- Krippl, Peter
- Melchardt, Thomas
- Petzer, Andreas
- Rumpold, Holger
- Sliwa, Thamer
- Wöhrer, Stefan
- Wölfler, Albert
- Gisslinger, Heinz
- SpringerLink (Online service)
Other Objects (12)
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Momelotinib therapy for myelofibrosis: a 7-year follow-up
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Momelotinib therapy for myelofibrosis: a 7-year follow-up
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Momelotinib therapy for myelofibrosis: a 7-year follow-up